Haematological effects of interferon-β-1a (Rebif®) therapy in multiple sclerosis

Drug Safety

Volumn 27, Issue 10, 2004, Pages 745-756

  Rieckmann, Peter ^a   O'Connor, Paul ^b   Francis, Gordon S ^c   Wetherill, Graham ^d,e   Alteri, Enrica ^f  

^a Department of Neurology ^*  (Germany)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c EMD SERONO INC   (United States)

^d Federal Institute for Vaccines and Biomedicines   (Switzerland)

^e Biometric Solutions Ltd   (United Kingdom)

^f Serono International   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BETA1A INTERFERON; CORTICOSTEROID; PLACEBO;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; BONE MARROW DEPRESSION; CELL LINEAGE; CONTROLLED STUDY; CYTOPENIA; DATA ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HERPES ZOSTER; HORMONAL THERAPY; HUMAN; JAUNDICE; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG INFECTION; LYMPHOCYTOPENIA; MALE; MULTIPLE SCLEROSIS; MYCOSIS; NEUTROPENIA; NEUTROPHIL; PAIN; PARASITOSIS; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGRANULOCYTOSIS; ANEMIA; BLOOD CELL COUNT; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INTERFERON-BETA; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 4344629219     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427100-00005     Document Type: Article

References (38)

1. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
3. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
4. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506
5. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
6. Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Saf 2000; 22 (2): 149-59
7. Walther EU, Hohfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622-7
8. Once Weekly Interferon for MS Study Group. Evidence of interferon B-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-86
9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82
10. Francis G, Grumser Y, Alteri E. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003; 26 (11): 815-27
11. SPECTRIMS Study Group, Hughes RAC. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
12. Sorensen PS, Andersen O, Elovaara I, et al. Double-blind placebo-controlled study of once weekly, low dose interferon beta-1a in secondary progressive multiple sclerosis (SPMS): Nordic SPMS study [abstract]. Mult Scler 2001; 7 Suppl. 1: S94
13. Rebif integrated summary of safety. Serono (Data on file)
14. Toccaceli F, Rosati S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepato Gastroenterology 1998; 45: 1748-52
15. Ernstoff MS, Lembersky BC, Kirkwood JM. Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol 1989; 7: 1764-5
16. Gugliotta L, Bagnara GP, Catani L, et al. In vivo and in vitro inhibitory effect of α-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989; 71: 177-81
17. Rotondi M, Mazziotti G, Biondi B, et al. Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves' disease. J Endocrinol Invest 2000; 23: 321-4
18. McDonald MD, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust N Z J Med 2000; 30: 278-9
19. Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment of multiple sclerosis. J Neurol Sci 1999; 162: 74-83
20. Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 2002; 97: 767-8
21. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115-50
22. Sevastianos VA, Deutsch M, Dourakis SP, et al. Pegylated interferon α-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003; 98: 406-707
23. Sagir A, Wettstein M, Heintges T, et al. Autoimmune thrombocytopenia induced by PEG-IFN-α 2b plus ribavirin in hepatitis C. Dig Dis Sci 2002; 47: 562-3
24. Tomita N, Motomura S, Ishigatsubo Y. Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia. Anticancer Drugs 2001; 12: 7-8
25. Landau A, Castera L, Buffet C, et al. Acute autoimmune hemolytic anemia during interferon alpha therapy for chronic hepatitis C. Dig Dis Sci 1999; 44: 1366-7
26. Kazuta Y, Watanabe N, Sagawa K, et al. A case of autoimmune hemolytic anemia induced by IFN-β therapy for type-C chronic hepatitis. Fukushima J Med Sci 1995; 41: 43-9
27. Aslam AK, Singh T. Aplastic anemia associated with interferon β-1a. Am J Ther 2002; 9: 522-3
28. Hrstkova H, Bajer M, Michalek J. Recombinant human interferon α-2a therapy in children with chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2002; 24: 299-303
29. Cesana C, Brando B, Boiani E, et al. Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-α. Eur J Haematol 2002; 68: 120-1
30. Barel C, Bilger K, Ninet J, et al. Treatment of hepatitis C virus-associated thrombocytopenic purpura with a combination of interferon alpha-2b and ribavirin. J Clin Gastroenterol 2002; 35: 200-1
31. Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 2001; 68: 202-9
32. Dikici B, Bosnak M, Kara IH, et al. Interferon-alpha therapy in idiopathic thrombocytopenic purpura. Pediatr Int 2001; 43: 577-80
33. Donato H, Kohan R, Picon A, et al. α-Interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2001; 23: 598-603
34. Vianelli N, Gugliotta L, Tura S, et al. Interferon-α2a treatment in a pregnant woman with essential thrombocythemia. Blood 1994; 83: 874-5
35. Berlex Laboratories. Betaseron® (interferon beta-1b) [package insert]. Berlex Laboratories, 2003
36. Panitch H. Differences between IFN beta-1A 44μg tiw and 30μg qw sustained to 16 months: final evidence results [abstract]. Int J MS Care 2003; 5: 80
37. Sandberg M. Comparative risk-benefit analysis in EVIDENCE [abstract]. Mult Scler 2003; 9: S139
38. Serono International. Rebif® (interferon beta-1a) [package insert]. Serono International, 2003